CD274 and gastric cancer: Current studies are also focusing on combination therapy with ICI, for example a dual target anti-TGFβ and anti-PD-L1 antibody (M7824) in combination with paclitaxel for second line treatment of recurrent or metastatic GC (NCT04835896).